Designed With Viral Safety in Mind
The only recombinant factor IX available to patients
BeneFIX is a leader in recombinant therapy for hemophilia B, with over 12 years of experience*
- Not derived from human blood
- Multiple purification steps plus nanofiltration
- No preservatives or added human or animal materials
- Chinese hamster ovary (CHO) cells used to manufacture BeneFIX are grown in media containing no added human or animal components
*BeneFIX was approved February 11, 1997.